Cargando…

Spontaneous remission in three cases of AML M5 with NPM1 mutation

Patients with NPM1-mutated AML M5 who develop spontaneous remission (SR) after antibiotic therapy at diagnosis seem to form a favorable prognosis and chemo sensitive subtype. We report three cases of AML M5 patients with the same genotype that experienced transient SR and are now leukemia free after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camus, Vincent, Etancelin, Pascaline, Jardin, Fabrice, Lenain, Pascal, Contentin, Nathalie, Daliphard, Sylvie, Buchonnet, Gérard, Lemasle, Emilie, Lanic, Hélène, Leprêtre, Stéphane, Penther, Dominique, Dubois, Sydney, Tilly, Hervé, Bastard, Christian, Stamatoullas, Aspasia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641483/ https://www.ncbi.nlm.nih.gov/pubmed/26576281 http://dx.doi.org/10.1002/ccr3.408

Ejemplares similares

Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report
por: Camus, Vincent, et al.
Publicado: (2023)

Cyberlindnera jadinii (teleomorph Candida utilis) candidaemia in a patient with aplastic anaemia: a case report
por: Treguier, Pauline, et al.
Publicado: (2018)

Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study
por: Camus, Vincent, et al.
Publicado: (2020)

Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first‐line treatment for patients with diffuse large B‐cell lymphoma
por: Pénichoux, Juliette, et al.
Publicado: (2022)

Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort
por: Bohers, Elodie, et al.
Publicado: (2018)

Successful treatment of T/myeloid mixed‐phenotype acute leukemia with the translocation (10;11)(p13;q14) PICALM/AF10 with 3 + 7 myeloid standard treatment: A case report
por: Krzisch, Daphné, et al.
Publicado: (2021)

Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11)
por: Chamseddine, A. N., et al.
Publicado: (2015)

Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas
por: Candon, Sophie, et al.
Publicado: (2021)

Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study
por: Pénichoux, Juliette, et al.
Publicado: (2023)

Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
por: Camus, Vincent, et al.
Publicado: (2018)

Multiple cutaneous ulcers revealing a primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma
por: Tedbirt, Billal, et al.
Publicado: (2020)

A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis
por: Penther, Dominique, et al.
Publicado: (2019)

Light chain lambda myeloma with fatal AL cardiac amyloidosis in a 21‐year‐old patient: A case report and review
por: Camus, Vincent, et al.
Publicado: (2019)

Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?
por: Dubois, Sydney, et al.
Publicado: (2015)

Significance of NPM1 Gene Mutations in AML
por: Hindley, Andrew, et al.
Publicado: (2021)

The antagonistic duality of NPM1 mutations in AML
por: Khan, Irum, et al.
Publicado: (2022)

NPM 1 Mutations in AML—The Landscape in 2023
por: Sharma, Naman, et al.
Publicado: (2023)

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
por: Gionfriddo, Ilaria, et al.
Publicado: (2021)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

Improving high-resolution copy number variation analysis from next generation sequencing using unique molecular identifiers
por: Viailly, Pierre-Julien, et al.
Publicado: (2021)

Concomitant occurrence of genetically distinct Hodgkin lymphoma and primary mediastinal lymphoma
por: Dubois, Sydney, et al.
Publicado: (2021)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
por: Duchmann, Matthieu, et al.
Publicado: (2022)

The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
por: Mill, Christopher P., et al.
Publicado: (2023)

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
por: Heiblig, Maël, et al.
Publicado: (2021)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
por: Mer, Arvind Singh, et al.
Publicado: (2021)

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
por: Falini, Brunangelo, et al.
Publicado: (2021)

Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML
por: Lopez, Amanda, et al.
Publicado: (2021)

NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML
por: Tregnago, Claudia, et al.
Publicado: (2021)

Current status and future perspectives in targeted therapy of NPM1-mutated AML
por: Ranieri, Roberta, et al.
Publicado: (2022)

Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice
por: Muranyi, Andrew, et al.
Publicado: (2022)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
por: Pinochet, Pierre, et al.
Publicado: (2021)

An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML
por: Dukka, Srivasavi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_unsseh1qb7c7atf3vims88akqe